Multicenter Expanded Access Protocol of Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Trial Profile

Multicenter Expanded Access Protocol of Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Tabelecleucel (Primary)
  • Indications Gastric cancer; Haemophagocytic lymphohistiocytosis; Leiomyosarcoma; Lymphoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder; Viraemia
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms EAP study
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 12 Dec 2017 Updated safety and efficacy data will be presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Interim results (n=10) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 Interim results were presented in an Atara Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top